Case Reports in Hematology
Volume 2012 (2012), Article ID 194797, 5 pages
Multiple Myeloma of the Thyroid Cartilage
Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
Received 15 December 2011; Accepted 28 January 2012
Academic Editor: C. Imai
Copyright © 2012 Peter Kalina and Jeffrey B. Rykken. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 60-year-old male presented with hoarseness. His past medical history was remarkable for a plasmacytoma of the left maxillary sinus having been resected without systemic evidence of plasma cell myeloma (PCM), also known as multiple myeloma (MM), at the time. This maxillary sinus disease recurred and was treated with radiation. Workup for PCM was conducted. Treatment included melphalan and autologous stem cell transplant. Because of the therapeutic and prognostic implications, a Plasma cell neoplasm (PCN) in a neck mass must be carefully evaluated by clinical and pathological criteria in order to distinguish plasmacytoma from PCM. PCN involvement of the thyroid cartilage is very rare, with only 5 previously reported cases.
Plasma cell neoplasms (PCNs) include extramedullary plasmacytoma (EMP), solitary bone plasmacytoma (SBP), and manifestation of plasma cell myeloma (PCM). EMP and SBP are benign and local. PCM is a systemic process and the most common PCN with the worst prognosis. Workup for PCM generally includes serum electrophoresis with evaluation for the presence of a monoclonal peak, consisting of IgG with kappa light chain. This case demonstrates the possibility of an indolent course of PCM with destructive laryngeal plasmacytoma without systemic findings. PCN accounts for less than 1% of head/neck tumors. Furthermore, PCN of the thyroid cartilage is very rare.
2. Case Report
A 60-year-old male presented with a three-month history of increasing hoarseness. Imaging was obtained consisting of a soft tissue neck MRI with noncontrast axial sequences (Figure 1), postcontrast coronal MRI and CT (Figure 2), postcontrast axial CT (Figure 3) and a nuclear medicine bone scan (Figure 4). His past medical history was remarkable for a plasmacytoma of the left maxillary sinus having been resected, although there was no systemic evidence of PCM at the time. This maxillary sinus disease recurred and was treated with radiation. Workup for PCM included serum electrophoresis demonstrating a monoclonal peak consisting of IgG with kappa light chain.
Initial bone marrow analysis demonstrated a slight increase in erythroid precursors and a slight decrease in granulocytic precursors. Plasma cells were borderline increased and estimated at 2-3% of the total cellularity. Immunohistochemical studies were essentially normal, other than a slight increase in plasma cell population identified via staining for CD138.
An additional bone marrow analysis was performed nearly seven months later. At this time, the patient was five-years out from the initial plasmacytoma resection. On this second marrow evaluation, panmyeloid hyperplasia was present and a tiny aggregate of atypical plasma cells was identified and deemed worrisome for early involvement of plasma cell neoplasm. Immunophenotyping was unable to be performed as too few plasma cells were present.
He initially had an early stage, indolent course of PCM with a destructive laryngeal plasmacytoma without systemic findings. In fact, an advanced destructive laryngeal lesion may exist with indolent PCM. Later skeletal surveys demonstrated multiple lytic lesions throughout the axial and appendicular skeleton. Treatment included high-dose melphalan and autologous stem cell transplant.
Plasma cell neoplasms (PCN) represent a monoclonal plasma cell proliferation. The three types, extramedullary plasmacytoma (EMP), solitary bone plasmacytoma (SBP), and manifestation of PCM (or multiple myeloma), represent distinct manifestations of the same disease, representing a disease continuum . EMP (3% of PCN) is a local plasma cell tumor outside of marrow. Of these, 50–60% progress to PCM . The larynx is involved in 5–20% cases but rarely involves the cartilage. SBP represents a local marrow plasma cell proliferation manifesting as an intraosseous lytic lesion. Of these, 20–30% progress to PCM . EMP and SBP are benign and local, without systemic disease or criteria of MM based on negative electrophoresis, bone marrow biopsy, and radiographs. PCM is the most common PCN. It is a systemic disease with disseminated involvement and thus has the worst prognosis. Findings include bone pain, anemia, renal failure, marrow plasmacytomas, lytic bone lesions, and a monoclonal gamma globulin peak. Patients may also have clinically silent disseminated extraosseous disease.
PCN accounts for less than 1% of head/neck tumors . EMP is usually a submucosal soft tissue mass in a paranasal sinus, nasal cavity, or nasopharynx. Most PCNs of the larynx represent EMP without PCM rather than extraosseous PCM. The most common symptom of laryngeal plasmacytoma is slowly progressive hoarseness. PCN of the thyroid cartilage is very rare.
There are two theories to explain cartilage involvement : direct cartilage invasion by adjacent plasmacytoma or metaplasia of cartilage to bone with formation of a marrow cavity in which a plasmacytoma originates. It is considered an extraosseous manifestation of PCM when cartilage is involved because it occurs in ossified cartilage rather than bone. It is rare compared with intramedullary PCM. Lesions are typically homogeneous, well defined, and enhancing. Uniformly expanded thyroid cartilage laminae and no soft tissue mass suggest that a plasmacytoma originates in the thyroid ala rather than being eroded by adjacent soft tissue plasmacytoma.
The three PCN variants are histologically indistinguishable. Because of the therapeutic and prognostic implications, a PCN in a neck mass must be carefully evaluated by clinical and pathological criteria in order to distinguish plasmacytoma from PCM.
Treatment of PCN of the larynx is local or wide excision as well as radiation (EMP/SBP are radiosensitive). Treatment of PCM includes melphalan/prednisolone, radiation for local control, and autologous bone marrow transplant with peripheral blood stem cells.
PCN involvement of the thyroid cartilage is very rare, with only 6 previously reported cases (Table 1) [1–6]. In 3 of these cases, the neck mass was the initial presenting feature of PCN. In 4 of 7 cases, including this case, hoarseness was a presenting feature of the thyroid cartilage lesion.
- I. Aslan, H. Yenice, and N. Baserer, “An indolent course of multiple myeloma mimicking a solitary thyroid cartilage plasmacytoma,” European Archives of Oto-Rhino-Laryngology, vol. 259, no. 2, pp. 84–86, 2002.
- T. Shimada, M. Matsui, K. Ikebuchi et al., “Multiple myeloma involving the thyroid cartilage,” Auris Nasus Larynx, vol. 34, no. 2, pp. 277–279, 2007.
- C. W. Van Dyke, T. J. Masaryk, and P. Lavertu, “Multiple myeloma involving the thyroid cartilage,” American Journal of Neuroradiology, vol. 17, no. 3, pp. 570–572, 1996.
- R. Saad, S. Raab, Y. Liu, P. Pollice, and J. F. Silverman, “Plasmacytoma of the larynx diagnosed by fine-needle aspiration cytology: a case report,” Diagnostic Cytopathology, vol. 24, no. 6, pp. 408–411, 2001.
- M. Gross, R. Eliashar, P. Petrova, A. Goldfarb, and J. Y. Sichel, “Neck mass as primary manifestation of multiple myeloma originating in the thyroid cartilage,” Otolaryngology—Head and Neck Surgery, vol. 126, no. 3, pp. 326–328, 2002.
- J. Sosna, B. S. Slasky, O. Paltiel, G. Pizov, and E. Libson, “Multiple myeloma involving the thyroid cartilage: case report,” American Journal of Neuroradiology, vol. 23, no. 2, pp. 316–318, 2002.
- P. Kalina and J. Rykken, “Multiple myeloma of the thyroid cartilage,” Case Reports in Hematology, vol. 2012, no. 11, pp. 1–5, 2012.